Back to News
Market Impact: 0.25
Intellia Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Business Updates
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Intellia Therapeutics reported a net loss of $127.5 million for the third quarter ended September 30, 2026, compared with a $101.3 million loss in the third quarter of 2025—an increase of $26.2 million. The article also mentions business updates but provides no further details in the supplied text.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
NTLA-0.30
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens